A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders.
Neuroimaging
Psychosis
Schizophrenia
Synaptic density
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
24
08
2023
accepted:
25
04
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
19
6
2024
Statut:
epublish
Résumé
Psychotic disorders have long been considered neurodevelopmental disorders where excessive synaptic pruning and cortical volume loss are central to disease pathology. We conducted a systematic review of the literature to identify neuroimaging studies specifically examining synaptic density across the psychosis spectrum. PRISMA guidelines on reporting were followed. We systematically searched MEDLINE, Embase, APA PsycINFO, Web of Science and The Cochrane Library from inception to December 8, 2023, and included all original peer-reviewed articles or completed clinical neuroimaging studies of any modality measuring synaptic density in participants with a diagnosis of psychosis spectrum disorder as well as individuals with psychosis-risk states. The NIH quality assessment tool for observational cohort and cross-sectional studies was used for the risk of bias assessment. Five studies (k = 5) met inclusion criteria, comprising n = 128 adults (psychotic disorder; n = 61 and healthy volunteers; n = 67 and specifically measuring synaptic density via positron emission tomography (PET) imaging of the synaptic vesicle glycoprotein 2 A (SV2A). Three studies were included in our primary meta-analysis sharing the same outcome measure of SV2A binding, volume of distribution (V Preliminary studies provide in vivo evidence for reduced synaptic density in psychotic disorders. However, replication of findings in larger samples is required prior to definitive conclusions being drawn. CRD42022359018.
Sections du résumé
BACKGROUND
BACKGROUND
Psychotic disorders have long been considered neurodevelopmental disorders where excessive synaptic pruning and cortical volume loss are central to disease pathology. We conducted a systematic review of the literature to identify neuroimaging studies specifically examining synaptic density across the psychosis spectrum.
METHODS
METHODS
PRISMA guidelines on reporting were followed. We systematically searched MEDLINE, Embase, APA PsycINFO, Web of Science and The Cochrane Library from inception to December 8, 2023, and included all original peer-reviewed articles or completed clinical neuroimaging studies of any modality measuring synaptic density in participants with a diagnosis of psychosis spectrum disorder as well as individuals with psychosis-risk states. The NIH quality assessment tool for observational cohort and cross-sectional studies was used for the risk of bias assessment.
RESULTS
RESULTS
Five studies (k = 5) met inclusion criteria, comprising n = 128 adults (psychotic disorder; n = 61 and healthy volunteers; n = 67 and specifically measuring synaptic density via positron emission tomography (PET) imaging of the synaptic vesicle glycoprotein 2 A (SV2A). Three studies were included in our primary meta-analysis sharing the same outcome measure of SV2A binding, volume of distribution (V
CONCLUSIONS
CONCLUSIONS
Preliminary studies provide in vivo evidence for reduced synaptic density in psychotic disorders. However, replication of findings in larger samples is required prior to definitive conclusions being drawn.
PROSPERO
UNASSIGNED
CRD42022359018.
Identifiants
pubmed: 38898401
doi: 10.1186/s12888-024-05788-y
pii: 10.1186/s12888-024-05788-y
doi:
Substances chimiques
Nerve Tissue Proteins
0
SV2A protein, human
148845-93-6
Membrane Glycoproteins
0
Types de publication
Systematic Review
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
460Subventions
Organisme : Slaight Family Center for Youth in Transition
ID : Seed funding Award
Organisme : Slaight Family Center for Youth in Transition
ID : Seed funding Award
Organisme : Slaight Family Center for Youth in Transition
ID : Seed funding Award
Organisme : Slaight Family Center for Youth in Transition
ID : Seed funding Award
Informations de copyright
© 2024. The Author(s).
Références
Ärnlöv J, Larsson A. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.
doi: 10.1016/S0140-6736(15)60692-4
McGlashan TH. Early detection and intervention in schizophrenia: research. Schizophr Bull. 1996;22(2):327–45.
doi: 10.1093/schbul/22.2.327
pubmed: 8782289
Cuthbert BN, Morris SE. Evolving concepts of the Schizophrenia Spectrum: A Research Domain Criteria Perspective. Front Psychiatry. 2021;12:641319.
doi: 10.3389/fpsyt.2021.641319
pubmed: 33716834
pmcid: 7947312
Laurens KR, et al. Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry. 2015;15:205.
doi: 10.1186/s12888-015-0562-2
pubmed: 26302744
pmcid: 4548447
Rogers J. A shared pathway connects schizophrenia and bipolar disorder. Nat Rev Neurosci. 2023;24(1):2.
doi: 10.1038/s41583-022-00662-w
pubmed: 36446901
Fisher HL, et al. Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study. Psychol Med. 2013;43(10):2077–86.
doi: 10.1017/S0033291712003091
pubmed: 23302254
pmcid: 3758773
Feinberg I. Cortical pruning and the development of schizophrenia. Schizophr Bull. 1990;16(4):567–70.
doi: 10.1093/schbul/16.4.567
pubmed: 2077635
Keshavan M, Lizano P, Prasad K. The synaptic pruning hypothesis of schizophrenia: promises and challenges. World Psychiatry. 2020;19(1):110–1.
doi: 10.1002/wps.20725
pubmed: 31922664
pmcid: 6953570
Mollon J, Reichenberg A. Cognitive development prior to onset of psychosis. Psychol Med. 2018;48(3):392–403.
doi: 10.1017/S0033291717001970
pubmed: 28735586
Howes OD, et al. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes. Neuropsychopharmacology. 2023;48(1):151–67.
doi: 10.1038/s41386-022-01426-x
pubmed: 36056106
Esterlis I, Holmes S. First in vivo evaluations of synaptic density alterations in the brain. Neuropsychopharmacology. 2022;47(1):381–2.
doi: 10.1038/s41386-021-01099-y
pubmed: 34285369
Navlakha S, Barth AL, Bar-Joseph Z. Decreasing-rate Pruning optimizes the construction of efficient and robust distributed networks. PLoS Comput Biol. 2015;11(7):e1004347.
doi: 10.1371/journal.pcbi.1004347
pubmed: 26217933
pmcid: 4517947
Huttenlocher PR. Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res. 1979;163(2):195–205.
doi: 10.1016/0006-8993(79)90349-4
pubmed: 427544
Tessier CR, Broadie K. Activity-dependent modulation of neural circuit synaptic connectivity. Front Mol Neurosci. 2009;2:8.
doi: 10.3389/neuro.02.008.2009
pubmed: 19668708
pmcid: 2724028
Sellgren CM, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22(3):374–85.
doi: 10.1038/s41593-018-0334-7
pubmed: 30718903
pmcid: 6410571
Forrest MP, Parnell E, Penzes P. Dendritic structural plasticity and neuropsychiatric disease. Nat Rev Neurosci. 2018;19(4):215–34.
doi: 10.1038/nrn.2018.16
pubmed: 29545546
pmcid: 6442683
van Berdenis A, et al. Synapse Pathology in Schizophrenia: a Meta-analysis of postsynaptic elements in Postmortem Brain studies. Schizophr Bull. 2020;46(2):374–86.
Calhoun ME, et al. Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol. 1996;25(12):821–8.
doi: 10.1007/BF02284844
pubmed: 9023727
Serrano ME, et al. Imaging synaptic density: the Next Holy Grail of Neuroscience? Front Neurosci. 2022;16:796129.
doi: 10.3389/fnins.2022.796129
pubmed: 35401097
pmcid: 8990757
Osimo EF, et al. Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Mol Psychiatry. 2019;24(4):549–61.
doi: 10.1038/s41380-018-0041-5
pubmed: 29511299
Eastwood SL, Burnet PW, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 1995;66(2):309–19.
doi: 10.1016/0306-4522(94)00586-T
pubmed: 7477874
Gogtay N, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A. 2004;101(21):8174–9.
doi: 10.1073/pnas.0402680101
pubmed: 15148381
pmcid: 419576
Andreou C, Borgwardt S. Structural and functional imaging markers for susceptibility to psychosis. Mol Psychiatry. 2020;25(11):2773–85.
doi: 10.1038/s41380-020-0679-7
pubmed: 32066828
pmcid: 7577836
Cannon TD, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2015;77(2):147–57.
doi: 10.1016/j.biopsych.2014.05.023
pubmed: 25034946
Schizophrenia Working Group of the Psychiatric Genomics. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.
doi: 10.1038/nature13595
Sekar A, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–83.
doi: 10.1038/nature16549
pubmed: 26814963
pmcid: 4752392
Lam M, et al. Pleiotropic Meta-analysis of Cognition, Education, and Schizophrenia differentiates roles of early neurodevelopmental and adult synaptic pathways. Am J Hum Genet. 2019;105(2):334–50.
doi: 10.1016/j.ajhg.2019.06.012
pubmed: 31374203
pmcid: 6699140
Grove J, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51(3):431–44.
doi: 10.1038/s41588-019-0344-8
pubmed: 30804558
pmcid: 6454898
Radhakrishnan R et al. In vivo evidence of lower synaptic vesicle density in schizophrenia. Mol Psychiatry, 2021.
Bajjalieh SM, et al. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14(9):5223–35.
doi: 10.1523/JNEUROSCI.14-09-05223.1994
pubmed: 8083732
pmcid: 6577109
Mercier J, Provins L, Valade A. Discovery and development of SV2A PET tracers: potential for imaging synaptic density and clinical applications. Drug Discov Today Technol. 2017;25:45–52.
doi: 10.1016/j.ddtec.2017.11.003
pubmed: 29233267
Finnema SJ, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8(348):348ra96.
doi: 10.1126/scitranslmed.aaf6667
pubmed: 27440727
Mattheisen M, et al. Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia. Schizophr Res. 2012;141(2–3):262–5.
doi: 10.1016/j.schres.2012.08.027
pubmed: 23017826
Halff EF, et al. Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. Behav Brain Res. 2021;405:113203.
doi: 10.1016/j.bbr.2021.113203
pubmed: 33636238
Holmes SE, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatry. 2022;27(4):2273–81.
doi: 10.1038/s41380-022-01465-2
pubmed: 35165397
pmcid: 9133063
Schmitt U, et al. The effects of GABA transporter inhibition on synaptophysin and synaptotagmin expression in diazepam tolerance. World J Biol Psychiatry. 2010;11(2 Pt 2):439–46.
doi: 10.3109/15622970902874932
pubmed: 19452356
Holmes SE, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10(1):1529.
doi: 10.1038/s41467-019-09562-7
pubmed: 30948709
pmcid: 6449365
Constantinescu CC, et al. Development and in vivo preclinical imaging of Fluorine-18-Labeled synaptic vesicle protein 2A (SV2A) PET Tracers. Mol Imaging Biol. 2019;21(3):509–18.
doi: 10.1007/s11307-018-1260-5
pubmed: 30084043
Li S, et al. Synthesis and in vivo evaluation of a novel PET Radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in Nonhuman Primates. ACS Chem Neurosci. 2019;10(3):1544–54.
doi: 10.1021/acschemneuro.8b00526
pubmed: 30396272
Nabulsi NB, et al. Synthesis and preclinical evaluation of 11 C-UCB-J as a PET Tracer for Imaging the synaptic vesicle glycoprotein 2A in the brain. J Nucl Med. 2016;57(5):777–84.
doi: 10.2967/jnumed.115.168179
pubmed: 26848175
Li S, et al. First-in-human evaluation of < sup > 18 F-SDM-8, a Novel Radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med. 2019;60(supplement 1):49–49.
Naganawa M, et al. First-in-human evaluation of (18)F-SynVesT-1, a Radioligand for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med. 2021;62(4):561–7.
doi: 10.2967/jnumed.120.249144
pubmed: 32859701
pmcid: 8049363
Finnema SJ, et al. Kinetic evaluation and test-retest reproducibility of [(11)C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. J Cereb Blood Flow Metab. 2018;38(11):2041–52.
doi: 10.1177/0271678X17724947
pubmed: 28792356
Li S, et al. Assessment of test-retest reproducibility of [(18)F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. Eur J Nucl Med Mol Imaging. 2021;48(5):1327–38.
doi: 10.1007/s00259-020-05149-3
pubmed: 33416954
Smart K, et al. Binding of the synaptic vesicle radiotracer [(11)C]UCB-J is unchanged during functional brain activation using a visual stimulation task. J Cereb Blood Flow Metab. 2021;41(5):1067–79.
doi: 10.1177/0271678X20946198
pubmed: 32757741
Bini J, et al. Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand (11)C-UCB-J. EJNMMI Res. 2020;10(1):83.
doi: 10.1186/s13550-020-00670-w
pubmed: 32666239
pmcid: 7359974
Becker G et al. The rise of synaptic density PET imaging. Molecules, 2020. 25(10).
Carson RE, et al. Imaging of synaptic density in neurodegenerative disorders. J Nucl Med. 2022;63(Suppl 1):S60–7.
doi: 10.2967/jnumed.121.263201
Heurling K, et al. Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Mol Cell Neurosci. 2019;97:34–42.
doi: 10.1016/j.mcn.2019.02.001
pubmed: 30796959
Sjoerd J, Finnema SL, Cai Z, Naganawa M, Chen M-K, Matuskey D et al. PET Imaging of Synaptic Vesicle Protein 2A, A.O. Rudi A.J.O. Dierckx, Erik F.J. de Vries, Aren van Waarde, Adriaan A. Lammertsma, Editor. 2021, Springer Cham.
Tang Y, et al. Detection of changes in synaptic density in amyotrophic lateral sclerosis patients using (18) F-SynVesT-1 positron emission tomography. Eur J Neurol. 2022;29(10):2934–43.
doi: 10.1111/ene.15451
pubmed: 35708508
Onwordi EC, et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun. 2020;11(1):246.
doi: 10.1038/s41467-019-14122-0
pubmed: 31937764
pmcid: 6959348
Onwordi EC, et al. Synaptic terminal density early in the course of Schizophrenia: an in vivo UCB-J Positron Emission Tomographic Imaging study of synaptic vesicle glycoprotein 2A. Biol Psychiatry; 2023.
Yoon JH, et al. Reductions in synaptic marker SV2A in early-course Schizophrenia. J Psychiatr Res. 2023;161:213–7.
doi: 10.1016/j.jpsychires.2023.02.026
pubmed: 36934603
Rossano S, et al. Assessment of a white matter reference region for (11)C-UCB-J PET quantification. J Cereb Blood Flow Metab. 2020;40(9):1890–901.
doi: 10.1177/0271678X19879230
pubmed: 31570041
Zhang H, et al. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. NeuroImage. 2012;61(4):1000–16.
doi: 10.1016/j.neuroimage.2012.03.072
pubmed: 22484410
Nazeri A, et al. In Vivo Imaging of Gray Matter Microstructure in Major Psychiatric disorders: opportunities for clinical translation. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5(9):855–64.
pubmed: 32381477
Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790–9.
doi: 10.1016/j.recesp.2021.06.016
pubmed: 34446261
Miller TJ, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–15.
doi: 10.1093/oxfordjournals.schbul.a007040
pubmed: 14989408
Riecher-Rossler A, et al. [The Basel Screening Instrument for psychosis (BSIP): development, structure, reliability and validity]. Fortschr Neurol Psychiatr. 2008;76(4):207–16.
doi: 10.1055/s-2008-1038155
pubmed: 18393134
Schultze-Lutter F, et al. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des. 2012;18(4):351–7.
doi: 10.2174/138161212799316064
pubmed: 22239566
Vollmer-Larsen A, Handest P, Parnas J. Reliability of measuring anomalous experience: the Bonn Scale for the Assessment of Basic symptoms. Psychopathology. 2007;40(5):345–8.
doi: 10.1159/000106311
pubmed: 17657133
Yung AR, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11–12):964–71.
doi: 10.1080/j.1440-1614.2005.01714.x
pubmed: 16343296
Healh NIo. Study Quality Assessment Tools. 2021 14 May 2023]; https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools .
Hooker JM, Carson RE. Human Positron Emission Tomography Neuroimaging. Annu Rev Biomed Eng. 2019;21:551–81.
doi: 10.1146/annurev-bioeng-062117-121056
pubmed: 31167104
Tufanaru C, et al. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc. 2015;13(3):196–207.
doi: 10.1097/XEB.0000000000000065
pubmed: 26355603
Alkan E, et al. Brain structural correlates of Metacognition in First-Episode Psychosis. Schizophr Bull. 2020;46(3):552–61.
doi: 10.1093/schbul/sbz116
pubmed: 31776577
Hanlon FM, et al. The clinical relevance of gray matter atrophy and microstructural brain changes across the psychosis continuum. Schizophr Res. 2021;229:12–21.
doi: 10.1016/j.schres.2021.01.016
pubmed: 33607607
pmcid: 8137524
Nazeri A, et al. Gray Matter Neuritic Microstructure Deficits in Schizophrenia and Bipolar Disorder. Biol Psychiatry. 2017;82(10):726–36.
doi: 10.1016/j.biopsych.2016.12.005
pubmed: 28073491
Parvathaneni P, et al. Gray Matter Surface based Spatial Statistics (GS-BSS) in Diffusion Microstructure. Med Image Comput Comput Assist Interv. 2017;10433:638–46.
pubmed: 29226284
pmcid: 5722235
Onwordi EC, et al. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Transl Psychiatry. 2021;11(1):393.
doi: 10.1038/s41398-021-01515-3
pubmed: 34282130
pmcid: 8290006
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.
doi: 10.1093/schbul/13.2.261
pubmed: 3616518
Maruff P, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2):165–78.
doi: 10.1093/arclin/acp010
pubmed: 19395350
Nuechterlein KH, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203–13.
doi: 10.1176/appi.ajp.2007.07010042
pubmed: 18172019
Deeks J, Higgins J, Altman D. Chap. 10: Analysing data and undertaking meta-analyses. Cochrane; 2019.
Leeson VC, et al. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr Res. 2009;107(1):55–60.
doi: 10.1016/j.schres.2008.08.014
pubmed: 18793828
pmcid: 2631642
Tsapakis EM, Dimopoulou T, Tarazi FI. Clinical management of negative symptoms of schizophrenia: an update. Pharmacol Ther. 2015;153:135–47.
doi: 10.1016/j.pharmthera.2015.06.008
pubmed: 26116809
Zelek WM, et al. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341–52.
doi: 10.1016/j.molimm.2019.07.030
pubmed: 31446305
Mah A, Geeraert B, Lebel C. Detailing neuroanatomical development in late childhood and early adolescence using NODDI. PLoS ONE. 2017;12(8):e0182340.
doi: 10.1371/journal.pone.0182340
pubmed: 28817577
pmcid: 5560526
Kraguljac NV, et al. Neurite Orientation Dispersion and Density Imaging in Psychiatric disorders: a Systematic Literature Review and a technical note. Biol Psychiatry Glob Open Sci. 2023;3(1):10–21.
doi: 10.1016/j.bpsgos.2021.12.012
pubmed: 36712566
Mak E, et al. In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. Neurobiol Aging. 2021;101:187–98.
doi: 10.1016/j.neurobiolaging.2021.01.016
pubmed: 33631470
pmcid: 8209289
Bennett MR. Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. Prog Neurobiol. 2011;95(3):275–300.
doi: 10.1016/j.pneurobio.2011.08.003
pubmed: 21907759
Appelbaum LG, et al. Synaptic plasticity and mental health: methods, challenges and opportunities. Neuropsychopharmacology. 2023;48(1):113–20.
doi: 10.1038/s41386-022-01370-w
pubmed: 35810199
Binda KH, et al. Exercise protects synaptic density in a rat model of Parkinson’s disease. Exp Neurol. 2021;342:113741.
doi: 10.1016/j.expneurol.2021.113741
pubmed: 33965411